论文部分内容阅读
目的探讨替吉奥联合奥沙利铂方案(SOX方案)和紫杉醇联合奥沙利铂和5-氟尿嘧啶方案(POF方案)治疗晚期胃癌的疗效和不良反应。方法收集2010年2月至2013年6月间晚期胃癌患者48例,分为SOX组和POF组,分别采用SOX方案(23例)和POF方案(25例)。至少完成2个周期化疗,比较两组患者的疗效和不良反应。结果 SOX组患者的有效率(RR)为47.8%,疾病控制率(DCR)为65.2%;POF组患者的RR为44.0%,DCR为68.0%,两组差异均无统计学意义(均P>0.05)。SOX组患者的中位疾病进展时间(TTP)为7.2个月,中位总生存期(OS)为11.5个月;POF组患者的TTP为8.4个月,OS为12.3个月,两组差异均无统计学意义(均P>0.05)。两组患者的不良反应也相似,以Ⅰ~Ⅱ级的血液学毒性和消化道反应为主。SOX组患者的血小板减少发生率高于POF组(P<0.05),POF组患者脱发发生率高于SOX组(P<0.05)。结论 SOX方案治疗晚期胃癌疗效与POF方案相似,耐受性好,应用更方便。
Objective To investigate the efficacy and adverse reactions of the combination of the tegaserod oxaliplatin (SOX) regimen and the paclitaxel plus oxaliplatin and the 5-fluorouracil regimen (POF regimen) in the treatment of advanced gastric cancer. Methods Forty-eight patients with advanced gastric cancer from February 2010 to June 2013 were divided into SOX group and POF group. SOX program (23 cases) and POF program (25 cases) were used respectively. At least two cycles of chemotherapy were completed and the efficacy and adverse reactions of the two groups were compared. Results In the SOX group, the RR was 47.8% and the disease control rate was 65.2%. In the POF group, the RR was 44.0% and the DCR was 68.0%. There was no significant difference between the two groups (P> 0.05). Patients in the SOX group had a median progression time (TTP) of 7.2 months and a median overall survival (OS) of 11.5 months; patients in the POF group had a TTP of 8.4 months and OS of 12.3 months No statistical significance (all P> 0.05). Adverse reactions in both groups were also similar, with predominantly hematological toxicities and digestive tract reactions of grade I-II. The incidence of thrombocytopenia in SOX group was higher than that in POF group (P <0.05). The incidence of hair loss in POF group was higher than that in SOX group (P <0.05). Conclusion The efficacy of SOX regimen in treating advanced gastric cancer is similar to POF regimen, and it is well tolerated and more convenient to use.